CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 183 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2023. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,210 | +282.2% | 116,322 | +299.5% | 0.04% | +260.0% |
| Q1 2024 | $1,363 | -70.0% | 29,119 | -77.2% | 0.01% | -66.7% |
| Q4 2023 | $4,543 | +427.6% | 127,682 | +341.2% | 0.03% | +275.0% |
| Q3 2023 | $861 | -75.1% | 28,939 | -84.9% | 0.01% | -71.4% |
| Q2 2023 | $3,459 | +46.4% | 191,974 | +30.5% | 0.03% | +40.0% |
| Q1 2023 | $2,363 | – | 147,116 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |